



HUTCHISON CHINA MEDITECH LTD

**For Immediate Release**

**26 July 2006**

**Hutchison China Meditech Limited (“Chi-Med”)**

**Notice of Maiden Interim Results**

Chi-Med, the pharmaceutical and healthcare group based primarily in China, will be announcing its maiden interim results for the six months ended 30 June 2006 on Wednesday 9 August 2006.

An analyst presentation will be held at 9.30am on the day, at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY.

Enquiries:

Citigate Dewe Rogerson +44 (0)20 7282 1050  
Yvonne Alexander

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and is listed on the Alternative Investment Market of the London Stock Exchange.

Chi-Med conducts pharmaceutical research and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs through its wholly owned Hutchison MediPharma subsidiary. Hutchison MediPharma aims to bring novel drugs to the global market for the treatment of cancer and auto-immune diseases by using modern drug discovery and development technologies and clinical standards that meet the requirements of ICH guidelines.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of the Hong Kong Stock Exchange.